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ABSTRACT
The homeobox-containing gene Hex is expressed in
several cell types, including thyroid follicular cells,
in which it regulates the transcription of tissue-
speci®c genes. In this study the regulation of
Hex promoter activity was investigated. Using co-
transfection experiments, we demonstrated that the
transcriptional activity of the Hex gene promoter in
rat thyroid FRTL-5 cells is ~10-fold greater than that
observed in HeLa and NIH 3T3 cell lines (which do
not normally express the Hex gene). To identify the
molecular mechanisms underlying these differ-
ences, we evaluated the effect of the thyroid-
speci®c transcription factor TTF-1 on the Hex
promoter activity. TTF-1 produced 3±4-fold
increases in the Hex promoter activity. Gel-
retardation assays and mutagenesis experiments
revealed the presence of functionally relevant TTF-1
binding sites in the Hex promoter region. These
in vitro data may also have functional relevance
in vivo, since a positive correlation between TTF-1
and Hex mRNAs was demonstrated in human
thyroid tissues by means of RT±PCR analysis. The
TTF-1 effect, however, is not suf®cient to explain
the difference in Hex promoter activity between
FRTL-5 and cells that do not express the Hex gene.
For this reason, we tested whether Hex protein is
able to activate the Hex promoter. Indeed, co-trans-
fection experiments indicate that Hex protein is able
to increase the activity of its own promoter in HeLa
cells ~4-fold. TTF-1 and Hex effects are additive:
when transfected together in HeLa cells, the Hex
promoter activity is increased 6±7-fold. Thus, the
contemporary presence of both TTF-1 and Hex
could be suf®cient to explain the higher transcrip-
tional activity of the Hex promoter in thyroid cells
with respect to cell lines that do not express the Hex
gene. These ®ndings demonstrate the existence
of direct cross-regulation between thyroid-speci®c
transcription factors.
INTRODUCTION
Regulation of gene expression occurs primarily at the
transcriptional level. Promoter-speci®c transcription factors
are a major class of transcriptional regulators (1,2). Some of
these factors are also tissue-speci®c, their expression being
restricted to a few cell types (3), and they play a major role in
the control of cell type-speci®c gene expression (4,5).
Therefore, these proteins are extremely important in the
control of differentiation, and they have also been implicated
in certain pathological states, such as cancer, which are
characterized by altered differentiation (6). Maintenance of a
differentiated phenotype is the result of integrated effects of
multiple tissue-speci®c transcriptional regulators (7). There-
fore, to understand the molecular mechanisms underlying the
differentiation of a given cell type, all or most of the tissue-
speci®c transcription factors operating in the cell must ®rst be
identi®ed and their functional relationships with one another
must be characterized.
The thyroid follicular cell (TFC) is an excellent model for
studies on the molecular mechanisms of cell type-speci®c
transcriptional regulation and differentiation. In fact, several
thyroid-speci®c transcription factors have been identi®ed and
characterized, including TTF-1, TTF-2, Pax8 and Hex (8,9).
Although also expressed in other tissues, their combination is
exclusive to TFC (8). These genes are expressed from the
beginning of thyroid development to the adult state and
inactivation of the genes in mice causes gross defects in
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thyroid gland morphogenesis and differentiation (8,10).
Moreover, inactivating mutations of these genes in humans
determine congenital hypothyroidism (11). Recent reports
have shown that thyroid-speci®c transcription factors establish
functional interactions with each other. For example, Hex is
able to decrease the TTF-1 and Pax8 activating effects in the
context of the thyroglobulin promoter (9). However, no
information is available on cross-regulation of thyroid-speci®c
transcription factors at the level of expression of their
respective genes.
The homeobox-containing gene Hex is expressed in several
tissues, including the thyroid gland (12,13). The promoter of
the mouse Hex gene has recently been identi®ed and
characterized (14±16). Studies in transgenic mice have
shown that distinct enhancer elements control Hex expression
during gastrulation and early organogenesis (17). Cell culture
studies have revealed a DNA element that mediates the
activating effects of HNF3b and GATA-4 (15), and it appears
to play a key role for Hex expression in the liver.
The objective of this study was to determine whether
thyroid-speci®c transcription factors are capable of regulating
Hex promoter activity. Our ®ndings show that this activity is
up-regulated by TTF-1 and by the Hex protein itself. We also
found a positive correlation between TTF-1 and Hex mRNA
levels in normal human thyroid tissues, suggesting that the
functional relationship observed in vitro may also be relevant
in vivo.
MATERIALS AND METHODS
Plasmids
The construct containing the mouse Hex promoter fragment
±235/+22 has been previously described (15). In this con-
struct, the fragment ±235/+22 of the Hex promoter was cloned
in the plasmid pGL3B, 5¢ to the luciferase (LUC) gene.
Plasmids containing mutations of the A and B TTF-1
binding sites of the Hex promoter were generated with the
QuickChange site-directed mutagenesis kit (Stratagene,
Milan, Italy), according to the manufacturer's instructions.
RSV-CAT and CMV-LUC plasmids contained the Rous
sarcoma virus and the cytomegalovirus promoters linked to
the chloranphenicol acetyltransferase (CAT) and LUC genes,
respectively. The TTF-1 and Hex expression vectors have
been previously described (9,18).
Cell cultures and transfections
NIH 3T3 and HeLa cells were cultured in DMEM medium
with 10% calf serum (Gibco, Milan, Italy). FRTL-5 cells were
maintained in F12 Coon's modi®ed medium with 5% calf
serum and hormone mixture as previously described (19). FRT
cells were grown in F12 Coon's modi®ed medium with 5%
fetal calf serum (20). The calcium phosphate co-precipitation
method was used for transfections, as described elsewhere
(21). HeLa and NIH 3T3 cells were plated at 6 3 105 cells/
100 mm culture dish, FRT cells were plated at 1.5 3 106 cells/
100 mm culture dish, 20 h prior to transfection. FRTL-5 cells
were plated at 1.5 3 106 cells/100 mm culture dish 48 h prior
to transfection, and 3 h prior to the addition of the DNA-
calcium phosphate precipitates, the medium was changed to
Dulbecco's modi®ed Eagle's medium containing 5% calf
serum and growth factors. The plasmids were used in the
following amounts: CMV-LUC, 2 mg; pGL3B, 8 mg; ±235/+22
Hex promoter (and relative mutants), 8 mg; TTF-1 expression
vector, 0.2, 0.5 and 2 mg; RSV-CAT, 2 mg; Hex expression
vector, 2 mg. Cells were harvested 42±44 h after transfection,
and cell extracts were prepared by a standard freeze and thaw
procedure. CAT activity was measured by an ELISA method
(Amersham, Milan, Italy). LUC activity was measured by a
chemiluminescence procedure (21).
Gel-retardation assay
TTF-1 binding to the Hex promoter region ±235/+22 was
investigated using a series of overlapping oligonucleotides
(data not shown). Double-stranded oligonucleotides, labeled
at the 5¢ end with 32P, were used as probes. The TTF-1
homeodomain (TTF-1HD) was used as protein, puri®ed as
described (22), and SDS±PAGE showed that it was >95%
pure. In the gel-retardation assays, protein and DNA (both at a
®nal concentration of 0.1 mM) were incubated for 30 min at
room temperature in a buffer containing 20 mM Tris±HCl
(pH 7.6), 75 mM KCl, 0.25 mg/ml bovine serum albumin,
5 mM dithiothreitol, 10 mg/ml calf thymus DNA and 10%
glycerol. Protein-bound DNA and free DNA were separated
on native 7.5% polyacrylamide gels run in 0.53 TBE for 1.5 h
at 4°C. Gels were dried and exposed to a Bio-Rad GS-525
Molecular Imager. Signi®cant TTF-1 binding was found with
the oligonucleotides Wt A (corresponding to the region ±162/
±146) and Wt B (corresponding to the region ±102/±86),
whose sense sequences are Wt A, 5¢-CGGGGGTTAGTG-
GGGGG-3¢, and Wt B, 5¢-CGGCAGGAAGGGGACCG-3¢.
The C site of the thyroglobulin gene promoter (sense
sequence, 5¢-CACTGCCCAGTCAAGTGTTCTTGA-3¢) was
used as a positive control (22). Nuclear extracts from HeLa
cells were prepared as previously reported (18).
RT±PCR in human tissues
Twelve differentiated thyroid tumors (®ve follicular and seven
papillary thyroid carcinomas) and nine non-nodular, normal
thyroid tissues were analyzed. Informed consent was obtained
from all patients. Total RNA extraction and cDNA synthesis
were performed as previously described (23) and the RT±PCR
ampli®cation was performed using 3 ml of cDNA as previously
described (24). As the HEX gene ampli®cation product was
produced in much greater amounts than the TTF-1 gene
ampli®cation product, to optimize the ratio of the two signals
all the samples were subjected to 10 cycles of ampli®cation
with TTF-1 primers only, then the PCR was paused (<2 min at
95°C) to add HEX primers. The samples were then subjected
to 25 cycles of ampli®cation. The PCR conditions were as
follows: a ®rst step of pre-denaturation at 95°C for 10 min,
Table 1. Comparison of Hex promoter activity in different cell lines
Cell line Promoter activitya
CMV RSV Hex
HeLa 100 53.5 33.8
NIH 3T3 100 34.6 39.6
FRTL-5 100 37.0 373.8
FRT 100 36.5 144.0
aPromoter activity is expressed as a percentage of CMV promoter activity.
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denaturation at 95°C for 30 s, annealing at 58°C for 30 s and
extension at 72°C for 30 s. Primer oligonucleotides for the
TTF-1 gene were 5¢-CTGTGCGTTTGTCGCTTACA-3¢ and
5¢-CGACAGGTACTTCTGTTGCT-3¢. The ampli®cation
yielded a 208 bp DNA product corresponding to fragment
1654±1862 of the TTF-1 gene according to the sequence
reported in GenBank (U19816.1). Primer oligonucleotides for
the HEX gene were 5¢-TACTCTGGAGCCCCTTCTTG-3¢
and 5¢-TTCAAGGTCTTCCTGGGAGG-3¢. The ampli®ca-
tion yielded a 370 bp DNA product corresponding to fragment
397±767 of the HEX gene according to the sequence reported
in GenBank (XM_018176). The reaction conditions were
optimized to ensure that ampli®cation for both the TTF-1 and
HEX genes remained within the exponential range. Different
ratios of primers were tested to get the same ef®ciency of
ampli®cation and the ratio 1:1 was used (data not shown).
Aliquots of 10 ml of 50 ml of the ampli®cation products were
run on 1.5 Tris±borate±EDTA agarose gels containing
ethidium bromide. The bands on the positive ®lm were
scanned and the density and the width of each PCR product
was measured using the NIH Image Program (Wayne
Rasband, National Institutes of Health, Bethesda, MD). The
correlation between Hex and TTF-1 transcript levels was
studied by linear regression analysis. A level of P < 0.05 was
considered statistically signi®cant.
RESULTS
Activity of the Hex promoter in thyroid cells
The mouse Hex promoter has recently been identi®ed (15). In
our experiments we used the construct Hex ±235/+22, which
contains 235 bp of the mouse Hex 5¢-¯anking sequence. In a
®rst set of experiments, we tested whether the transcriptional
activity of this construct was different between differentiated
thyroid cell lines (FRTL-5 and FRT cells) and other cell lines,
which do not express the Hex gene (HeLa and NIH 3T3). As
shown in Table 1, when the activity of the RSV promoter is
normalized to that of the CMV promoter, it is similar in the
four cell lines. In contrast, transcription of the Hex ±235/+22
construct in FRTL-5 cells was 10 times greater than that
observed in HeLa and NIH 3T3 cells. However, in FRT cells,
which express a different pattern of thyroid-speci®c transcrip-
tion factors (25), the activity of the Hex ±235/+22 promoter
was 2.5 times lower than that observed in FRTL-5, but still
higher than HeLa and NIH 3T3 cells. These results indicate
that mechanisms capable of enhancing the transcriptional
Figure 1. TTF-1 effect on the ±235/+22 Hex promoter. HeLa and NIH 3T3 cell lines were transfected as described in Materials and Methods. The activity of
each promoter was normalized for the ef®ciency of transfection using the RSV-CAT construct. Results are expressed as percentages of the activity of
the CMV promoter. EV, empty pGL3B vector; ±235, ±235/+22 mouse Hex promoter. Each bar represents the mean value (6SD) of three independent
transfections.
Figure 2. TTF-1 binding sites in the ±235/+22 Hex promoter. (A) Wild-
type and mutant sequences of the mouse Hex promoter. (B) Gel-retardation
assays of oligonucleotides containing sequences indicated in (A). TTF-1HD
was used as the protein. B, protein-bound DNA; F, free DNA.
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activity of the Hex promoter are operative in thyroid cells but
not in cell lines that do not express the Hex gene.
Effects of TTF-1 on the Hex promoter
One of the simplest explanations for the difference described
above is that Hex promoter activity in thyroid cells is affected
by tissue-speci®c transcriptional activators that are not found
in the other cells lines we examined. TTF-1 seemed to be a
likely candidate for this role, since it has been shown to
activate most of the thyroid-speci®c promoters assayed thus
far (8), and it is expressed in FRTL-5 cells but not in FRT cells
(25). To test this hypothesis, we evaluated the effects of TTF-1
on Hex promoter activity in non-thyroid cells. HeLa cells and
NIH 3T3 cells were transfected with the Hex ±235/+22
construct, with and without a TTF-1 expression vector. The
CMV promoter was used to normalize the promoter activities.
The results are shown in Figure 1. In HeLa cells TTF-1
increased the transcriptional activity of the Hex promoter 3- or
4-fold. The TTF-1 effect was much more modest in NIH 3T3
cells; in fact, an increase in transcriptional activity was
present, but <1-fold. These data indicate that TTF-1 increases
activity of the Hex promoter when expressed in non-thyroid
cells. However, the extent of the up-regulation induced by
TTF-1 is cell type-dependent. Nevertheless, these data suggest
that the increased transcriptional activity of the Hex promoter
in thyroid cells with respect to non-thyroid cells was due, at
least partially, to the action of TTF-1.
TTF-1 binding sites on the Hex promoter
In order to identify TTF-1 binding sites on the Hex promoter,
overlapping oligonucleotides covering the entire ±235/+22
DNA sequence were tested in gel-retardation assays, using
TTF-1HD as the bound protein (data not shown). The C site of
the thyroglobulin promoter (known to contain a high-af®nity
Figure 3. Effect of mutation of TTF-1 binding sites on the activity of Hex promoter. (A) Effect of single mutations indicated in Figure 2 on the ±235/+22
Hex promoter activity. The activity of each promoter was normalized for the ef®ciency of transfection using the RSV-CAT construct. Results are expressed
as percentage of the ±235/+22 Hex promoter in the absence of TTF-1. Each bar represents the mean value (6SD) of four independent transfections. (B) Effect
of the double mutation (Mut A+B). Each dot represents the mean value (6SD) of three independent transfections. (C) Effects of the wild-type and Mut A+B
promoters on Hex expression in transfected HeLa cells. The gel-retardation assay was performed by using the C site of the thyroglobulin promoter as labeled
probe and 6 mg of HeLa nuclear extracts. Competitor DNAs were used at 50-fold molar excess with respect to the labeled C probe. Cb is a mutant of the C
site, in which the TTF-1 binding site has been abolished (9). F, free DNA; B(NS), non-speci®c binding activity; B(S), speci®c TTF-1 binding. Note that
B(NS) is present also in untransfected HeLa cells.
1848 Nucleic Acids Research, 2003, Vol. 31, No. 7
TTF-1 binding site) (22) was used as a positive control. Two
TTF-1 binding sites were found within the ±235/+22
sequence, the ®rst located between nucleotides ±162 and
±146 (site A) and the second between nucleotides ±102 and
±86 (site B) (Fig. 2A). To assess the transcriptional relevance
of these TTF-1 binding sequences, mutants were designed
to abolish TTF-1 binding at each of these sites (Fig. 2A).
Gel-retardation assays demonstrated that the introduced
nucleotide changes abolished TTF-1HD binding to both sites
(Fig. 2B). Each of the mutant sequences was then incorporated
into the Hex ±235/+22 promoter construct, and the activity of
the mutant promoters was tested by co-transfecting HeLa cells
with the TTF-1 expression vector. Mutations at either site
diminished the activating effect of TTF-1 on the Hex ±235/
+22 promoter (Fig. 3A). Mutant A has a basal activity
signi®cantly higher than the Hex wild-type promoter. Both the
A and B mutant promoters are transactivated by TTF-1
<2-fold (using 0.5 mg of TTF-1 expression vector). A Hex
±235/+22 construct containing both the A and B mutations
was then generated (Mut A+B) and its activity assayed in
HeLa cells, using different amounts of TTF-1 expression
vector. Figure 3B shows that 0.2 and 0.5 mg of TTF-1
expression vector activated the wild-type Hex promoter but
not the Mut A+B Hex promoter. At a higher dose of TTF-1
expression vector (2 mg) the Hex A+B mutant was also
transactivated, but much less than the wild-type promoter. A
possible explanation of this latter ®nding could be the
presence of additional, lower af®nity TTF-1 binding sites
(data not shown). Figure 3C shows gel-retardation assays of
HeLa cells transfected with either the wild-type or the A+B
mutant Hex promoter and different amounts of TTF-1
expression vector. As shown, the A+B mutant promoter did
not modify the amount of TTF-1 protein, excluding inhibitory
effects of the Hex A+B mutant promoter on the expression of
TTF-1. These data indicate that the activating effect exerted
by TTF-1 on the Hex promoter is due, at least in part, to a
direct protein±DNA interaction.
Correlation between TTF-1 and HEX gene expression in
human thyroid
To verify the existence of a functional interaction between
TTF-1 and the Hex promoter in vivo, we measured TTF-1 and
the Hex mRNA levels in both normal and neoplastic human
thyroid tissues by means of multiplex PCR, as described in
Materials and Methods. As shown in Figure 4, TTF-1 mRNA
levels displayed a signi®cant correlation with those of HEX
both in normal thyroid tissues (r2 = 0.66, P = 0.0081) and in
differentiated thyroid neoplasms (papillary and follicular
carcinomas) (r 2 = 0.54, P = 0.0065), which is compatible
with our hypothesis that TTF-1 regulates HEX promoter
activity in vivo. The absence of such a correlation would have
indicated that the functional interaction observed in vitro had
no in vivo relevance.
Effect of Hex protein on the Hex promoter
Data obtained in the co-transfection experiments (Fig. 1)
indicated that TTF-1 increases Hex promoter activity by
3±4-fold. However, as shown in Table 1, the activity of the
Hex promoter in thyroid cells was roughly 10 times higher
than that of other cell lines, suggesting that TTF-1 is not the
only tissue-speci®c factor that in¯uences Hex promoter
activity in thyroid cells. Since the Hex protein itself is a
transcription factor (26), we suspected that it might also exert
modulatory effects on its own gene promoter. We tested this
hypothesis by transfecting NIH 3T3 and HeLa cells with the
Hex ±235/+22 promoter, with and without a Hex expression
vector. Figure 5 shows the results. In agreement with previous
observations indicating Hex as a transcriptional repressor
(9 and references therein), the Hex protein was found to
suppress the activity of the RSV promoter in NIH 3T3 cells.
Figure 4. HEX and TTF-1 mRNA detection by semi-quantitative RT±PCR in normal human thyroid tissues. (Left) Normal tissues; (right) papillary and
follicular carcinomas. (Top) Example of agarose gel electrophoresis of RT±PCR ampli®ed human HEX and TTF-1 mRNA genes. Expected bands are indi-
cated by black arrows. To determine the relative expression levels of these genes the positive bands were scanned and the density and the width of each PCR
product was measured as described in Materials and Methods. Values of Hex and TTF-1 expression were correlated in the graphs at the bottom of the ®gure.
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However, in our experimental conditions, Hex protein had no
inhibitory effects on the RSV promoter in HeLa cells (Fig. 5A).
Both in NIH 3T3 and in HeLa cells, Hex protein increased the
transcriptional activity of the Hex ±235/+22 promoter (10- and
4-fold, respectively). Hence, a positive regulatory loop
between the Hex gene promoter and the protein product may
be hypothesized.
Once it had been demonstrated that Hex protein was able to
activate its own promoter, the effect of the concurrent
presence of TTF-1 and Hex proteins on Hex promoter activity
was tested. Co-transfection experiments were performed in the
HeLa cell line. In this cell line, in fact, the RSV promoter
(used to normalize for transfection ef®ciency) was not
inhibited by Hex protein (Fig. 5B). The results are shown in
Figure 5B. Both TTF-1 (using 0.5 mg of expression vector) and
Hex protein (using 2.0 mg of expression vector) increased Hex
promoter activity by ~3- and 2-fold, respectively. When
TTF-1 and Hex expression vectors were transfected together,
the Hex promoter activity increased 6- or 7-fold. Therefore,
the TTF-1 and Hex proteins exert additive effects on the Hex
promoter. Interestingly, in HeLa cells expressing both TTF-1
and Hex proteins the Hex promoter reached a transcriptional
activity similar to that observed in FRTL-5 cells (compare
results shown in Table 1 and Fig. 5). Thus, the contemporary
presence of both TTF-1 and Hex could be suf®cient to explain
the higher transcriptional activity of the Hex promoter in
FRTL-5 cells with respect to HeLa cells.
DISCUSSION
Several examples in a wide range of organisms indicate that
tissue-speci®c gene expression is the result of functional
interactions between distinct tissue-speci®c transcriptional
regulators (7,27,28). Cross-talk of this type could theoretically
occur at three levels: (i) protein±protein interactions
between the transcription factors themselves; (ii) protein±
DNA interactions involving the binding of different combin-
ations of transcription factors to promoter/enhancer regions of
target genes; (iii) protein±DNA interactions between one or
more transcription factors and the regulatory regions of genes
encoding other transcription factors. In a previous study (9),
we demonstrated functional interaction among tissue-speci®c
transcription factors in thyroid cells at the level of common
target genes, i.e. Hex-induced repression of the thyroglobulin
promoter activating effects of TTF-1 or Pax8. Our present
®ndings indicate that cross-regulation of thyroid-speci®c
transcription factors also involves interaction between the
factors themselves and the promoter regions of genes for other
transcription factors.
It has been previously shown that in Hex-null mice
development of the thyroid is arrested at the budding stage at
9.5 days post coitum (10) and, at this stage, the thyroid
primordium is characterized by the absence of TTF-1. These
®ndings indicate that Hex controls TTF-1 gene expression.
The results of our study indicate that the reverse also occurs,
i.e. TTF-1 controls Hex expression. Collectively, these
observations suggest the existence of a positive feedback
loop between TTF-1 and Hex.
We have recently shown that Hex expression is retained in
most human thyroid undifferentiated carcinomas (29),
although TTF-1 expression is abolished (30,31). In these
Figure 5. Hex transactivates its own promoter and has an additive effect
with TTF-1. (A) The ±235/+22 Hex promoter construct (containing the
LUC gene as reporter) and the RSV promoter construct (containing the
CAT gene as reporter) were co-transfected in NIH 3T3 and HeLa cells with
and without 2 mg of the Hex expression vector. LUC and CAT were
measured as described in Materials and Methods. (B) The ±235/+22 Hex
construct was used as test promoter. TTF-1 and Hex expression vectors
were used at concentrations of 0.5 and 2 mg/dish, respectively.
Transfections and measurement of the reporter gene were performed as de-
scribed in Materials and Methods. Each bar represents the mean value
(6SD) of four independent transfections.
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neoplasms, therefore, Hex promoter activity seems to be
maintained by factors other than TTF-1, which is consistent
with our observation in the present study of signi®cant basal
Hex promoter activity in the absence of TTF-1, both in HeLa
and NIH 3T3 cells (see Fig. 1). Therefore, under certain
conditions, the presence of TTF-1 may not be essential for the
activation of the Hex promoter. Within this context, it is
interesting to recall that Kikkawa et al. have recently
demonstrated that ubiquitous transcription factors are also
involved in the activation of the Hex promoter (16).
Nevertheless, the correlation between HEX and TTF-1
mRNA levels, which we found in both normal and neoplastic
human thyroid tissue, strengthens the hypothesis that TTF-1
does indeed regulate Hex expression. The absence of this
correlation would have indicated that the TTF-1 effect on the
Hex promoter is not relevant in normal human thyroid tissue.
It must be pointed out, however, that the correlation between
TTF-1 and Hex might just as well be a re¯ection of other types
of control mechanisms. For example, TTF-1 gene expression
might be regulated by Hex, rather than vice versa, and this
possibility is also suggested by the disappearance of TTF-1
mRNA in Hex-null mice (10). Alternatively, there might be an
upstream control mechanism that modulates the expression of
both the TTF-1 and Hex genes in the same direction, without
any form of functional interaction between the two factors
themselves. In our opinion, however, this latter mechanism is
unlikely: the fact that TTF-1 expression, but not that of Hex, is
suppressed in most undifferentiated thyroid carcinomas
(29,30) suggests separate mechanisms of control for the
expression of these two transcription factors.
Early investigations indicated that the Hex protein is a
transcriptional repressor (32). Indeed, the activity of the
thyroglobulin gene promoter is inhibited by Hex expression
(9). However, more recent data indicate that Hex protein may
also act as a transcriptional activator (26). Altogether, our data
indicate that the Hex protein transcriptional effects are
dependent on cell types and target promoters. The interaction
between Hex and the promoter region of its gene re¯ects a
positive feedback loop, which is probably important for
maintenance of Hex expression. Interestingly, a similar
phenomenon has been described for TTF-1 (33), suggesting
that positive feedback of this type is common in thyroid cells.
A mechanism of this type might contribute to the maintenance
of the differentiated phenotype once other events have
triggered initial expression of tissue-speci®c transcription
factors.
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